Clinical pharmacokinetics of alfentanil, fentanyl and sufentanil. An update

Clinical Pharmacokinetics

Volumn 31, Issue 4, 1996, Pages 275-292

  Scholz, Jens ^a   Steinfath, Markus ^a   Schulz, Martin ^b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Drug Information Center   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALFENTANIL; CIMETIDINE; DEXMEDETOMIDINE; ERYTHROMYCIN; FENTANYL; HALOTHANE; NARCOTIC ANALGESIC AGENT; OPIATE RECEPTOR; PLASMA PROTEIN; PROPOFOL; SUFENTANIL;

ACID BASE BALANCE; AGE; ANALGESIA; CARDIOPULMONARY BYPASS; COMPUTER SIMULATION; DOSE TIME EFFECT RELATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; HEART SURGERY; INTENSIVE CARE; KIDNEY DISEASE; LIVER BLOOD FLOW; LIVER DISEASE; LONG TERM CARE; OBESITY; PHARMACOKINETICS; PRIORITY JOURNAL; REVIEW; SEDATION;

EID: 0029820849     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199631040-00004     Document Type: Review

References (136)

1. Evans CJ, Keith DE, Morrison H, et al. Cloning of a delta opioid receptor by functional expression. Science 1992; 258: 1952-5
2. Kiefer BL, Befort K, Gaveriaux-Ruff C, et al. The delta-opioid receptor: isolation of a cDNA by expression cloning and pharmacologic characterization. Proc Natl Acad Sci USA 1992; 89: 12048-52
3. Chen Y, Mestek A, Liu J, et al. Molecular cloning and functional expression of a μ-opioid receptor from rat brain. Mol Pharmacol 1993; 44: 8-12
4. Fakuda K, Kato S, Mori K, et al. Primary structures and expression from cDNAs of rat opioid receptor delta- and μ-subtypes. FEBS Lett 1993; 327: 311-4
5. Nishi M, Takeshima H, Fukuda K, et al. cDNA cloning and pharmacological characterization of an opioid receptor with high affinities for kappa-subtype-selective ligands. FEBS Lett 1993; 330: 77-80
6. Yasuda K, Raynor K, Kong H, et al. Cloning and functioning comparison of kappa and delta opioid receptors from mouse brain. Proc Natl Acad Sci USA 1993; 90: 6736-40
7. Holaday JW, Tortella FC. Multiple opioid receptors: possible physiological functions of μ and delta binding sites in vivo. In: Genazzini AR, Müller EE, editors. Central and peripheral endorphins: basis and clinical aspects. New York: Raven Press, 1984: 237-50
8. Pleuvry BJ. Opioid receptors and their ligands: natural and unnatural. Br J Anaesth 1991; 66: 370-80
9. Pasternak GW. Pharmacological mechanisms of opioid analgesics. Clin Neuropharmacol 1993; 16: 1-18
10. Soudijn W. The pharmacology and pharmacokinetics of fentanyl. In: Wood TD, editor. Stress-free anaesthesia. London: Royal Society of Medicine, 1978: 4-10
11. Hug Jr CC. Pharmacokinetics of new synthetic narcotic analgesics. In: Estafanous F, editor. Opioids in anesthesia. Boston: Butterworth, 1984: 55-60
12. Freye E. Opioide in der Medizin. Wirkung und Einsatzgebiete zentraler Analgetika, 3. Auflage. Berlin: Springer 1995: 181-6
13. Olkkola KT, Hamunen K, Maunuksela EL. Clinical pharmacokinetics and pharmacodynamics of opioid analgesics in infants and children. Clin Pharmacokinet 1995; 28: 385-404
14. Freye E. Opioide - Zentrale Analgetika. Ihre Wirkweise beim Menschen. DIAGM 1991; 12: 1105-18
15. Yun CH, Wood M, Wood AJ, et al. Identification of the pharmacogenetic determinants of alfentanil metabolism: cytochrome P-450 3A4. An explanation of the variable elimination clearance. Anesthesiolgy 1992; 77: 467-74
16. Kharasch ED, Thummel KE. Human alfentanil metabolism by cytochrome P450 3A3/4: an explanation for the interindividual variability in alfentanil clearance? Anesth Analg 1993; 76: 1033-9
17. McClain DA, Hug Jr CC. Intravenous fentanyl kinetics. Clin Pharmacol Ther 1980; 28: 106-14
18. Meuldermans W, Hendrick J, Lauwers W. Excretion and biotransformation of alfentanil and sufentanil in rats and dogs. Drug Metab Dispos 1987; 15: 905-13
19. Gupta SK, Southam MA, Hwang SS. Evaluation of diurnal variation in fentanyl clearance. J Clin Pharmacol 1995; 35: 159-62
20. Lehmann KA, Sipakis K, Gasparini R, et al. Pharmacokinetics of sufentanil in general surgical patients under different conditions of anaesthesia. Acta Anaesthesiol Scand 1993; 37: 176-80
21. Burm AGL, Ausems MEM, Spierdijk J, et al. Pharmacokinetics of alfentanil administered at a variable rate during three types of surgery. Eur J Anaesthesiol 1993; 10: 241-51
22. Scholz J, Bause H, Schulz M, et al. Pharmacokinetics and effects on intracranial pressure of sufentanil in head trauma patients. Br J Clin Pharmacol 1994; 38: 369-72
23. Monk JP, Beresford R, Ward A. Sufentanil: a review of its pharmacological properties and therapeutic use. Drugs 1988; 36: 286-313
24. Clotz MA, Nahata MC. Clinical uses of fentanyl, sufentanil, and alfentanil. Clin Pharm 1991; 10: 581-93
25. Bovill JG, Sebel PS, Blackborn CL, et al. The pharmacokinetics of sufentanil in surgical patients. Anesthesiology 1984; 61: 502-6
26. Davis JP, Cook DR, Stiller PL, et al. Pharmacodynamics and pharmacokinetics of high-dose sufentanil in infants and children undergoing cardiac surgery. Anesth Analg 1987; 66: 203-8
27. Greeley WJ, de Bruijn NP, Davis DP. Sufentanil pharmacokinetics in pediatric cardiovascular patients. Anesth Analg 1987; 66: 1067-72
28. Hudson RJ, Bergstrom RG, Thomson IR, et al. Pharmacokinetics of sufentanil in patients undergoing abdominal aortic surgery. Anesthesiology 1989; 70: 426-31
29. Davis JP, Stiller RL, Cook DR, et al. Pharmacokinetics of sufentanil in adolescent patients with chronic renal failure. Anesth Analg 1988; 67: 268-71
30. Fyman PN, Reynolds JR, Moser F, et al. Pharmacokinetics of sufentanil in patients undergoing renal transplantation. Can J Anaesth 1988; 35: 312-5
31. Matteo RS, Schwartz AE, Ornstein E, et al. Pharmacokinetics of sufentanil in the elderly surgical patient. Can J Anaesth 1990; 37: 852-6
32. Guay J, Gaudreault P, Tang A, et al. Pharmacokinetics of sufentanil in normal children. Can J Anaesth 1992; 39: 14-20
33. Alazia M, Albanese J, Martin C, et al. Pharmacokinetics of long-term sufentanil infusion (72 hours) used for sedation in ICU patients [abstract]. Anesthesiology 1992; 77: A364
34. Bodenham A, Park GR. Alfentanil infusions in patients requiring intensive care. Clin Pharmacokinet 1988; 15: 216-26
35. Willens JS, Myslinski NR. Pharmacodynamics, pharmacokinetics, and clinical uses of fentanyl, sufentanil, and alfentanil. Heart Lung 1993; 22: 239-51
36. Sawchuk CWT, Ong B, Unruh HW, et al. Thoracic versus lumbar epidural fentanyl for postthoracotomy pain. Ann Thorac Surg 1993; 55: 1472-6
37. Baxter AD, Laganiere S, Samon B, et al. A comparison of lumbar epidural and intravenous fentanyl infusions for post-thoracotomy analgesia. Can J Anaesth 1994; 41: 184-91
38. Salomaki TE, Laitinen JO, Nuutinen LS. A randomized double-blind comparison of epidural versus intravenous fentanyl infusion for analgesia after thoracotomy. Anesthesiology 1991; 75: 790-5
39. Sandler AN, Stringer D, Panos L, et al. A randomized double-blind comparison of lumbar epidural and intravenous fentanyl infusions for post-thoracotomy pain relief. Anesthesiology 1992; 77: 626-34
40. Guinard JP, Mavrocordatos P, Chiolero R, et al. A randomized comparison of intravenous versus lumbar and thoracic epidural fentanyl for analgesia after thoracotomy. Anesthesiology 1992; 77: 1108-15
41. Camu F, Debucquoy F. Alfentanil infusion for postoperative pain: a comparison of epidural and intravenous routes. Anesthesiology 1991; 75: 171-8
42. Chauvin M, Hongnat JM, Mourgeon E, et al. Equivalence of postoperative analgesia with patient-controlled intravenous or epidural alfentanil. Anesth Analg 1993; 76: 1251-8
43. Taverne RHT, Ionescu TI, Nuyten STM. Comparative absorption and distribution pharmacokinetics of intravenous and epidural sufentanil for major abdominal surgery. Clin Pharmacokinet 1992; 23: 231-7
44. Geller E, Chrubasik J, Graf R, et al. A randomized double-blind comparison of epidural sufentanil versus intravenous sufentanil or epidural fentanyl analgesia after major abdominal surgery. Anesth Analg 1993; 76: 1243-50
45. Camann WR, Denney RA, Holby ED, et al. A comparison of intrathecal, epidural, and intravenous sufentanil for labor analgesia. Anesthesiology 1992; 77: 884-7
46. Naulty JS, Barnes D, Becker R, Pate A. Continuous subarachnoid sufentanil for labor analgesia [abstract]. Anesthesiology 1990; 73: A964
47. Honet JE, Arkoosh VA, Huffnagle HJ, et al. Comparison of fentanyl, meperidine, and sufentanil for labor analgesia [abstract]. Anesthesiology 1991; 75: A839
48. Coda BA, Brown MC, Schaffer R, et al. Pharmacology of epidural fentanyl, alfentanil, and sufentanil in volunteers. Anesthesiology 1994; 81: 1149-61
49. Cooper DW, Ryall DM, Desira WR. Extradural fentanyl for postoperative analgesia: predominant spinal or systemic action? Br J Anaesth 1995; 74: 184-7
50. Hansdottir V, Woestenborghs R, Nordberg G. The cerebrospinal fluid and plasma pharmacokinetics of sufentanil after thoracic or lumbar epidural administration. Anesth Analg 1995; 80: 724-9
51. Swenson JD, Hullander M, Bready RJ. A comparison of patient controlled epidural analgesia with sufentanil by the lumbar versus thoracic route after thoracotomy. Anesth Analg 1994; 78: 215-8
52. Verborgh C, Claeys M, Vanlersberghs C, et al. Postoperative pain treatment after cholecystectomy with epidural sufentanil at lumbar or thoracic level. Acta Anaesthesiol Scand 1994; 38: 218-22
53. Sandler AN. Transdermal fentanyl: acute analgesic studies. J Pain Symptom Manage 1992; 7: S27-S35
54. Sandler AN, Baxter AD, Samson B, et al. Postoperative analgesia with transdermal fentanyl: analgesic and respiratory effects [abstract]. Can J Anaesth 1993; 40: A51
55. Fiset P, Cohane C, Browne S, et al. Biopharmaceutics of a transdermal fentanyl device. Anesthesiology 1995; 83: 459-69
56. Varvel JR, Shafer SL, Hwang S, et al. Bioavailability and absorption of transdermal fentanyl. Anesthesiology 1989; 70: 928-34
57. Sebel PS, Barrett CW, Kirk CJC, et al. Transdermal absorption of fentanyl and sufentanil in man. Eur J Clin Pharmacol 1987; 32: 529-31
58. Calis KA, Kohler DR, Corso DM. Transdermally administered fentanyl for pain management. Clin Pharm 1992; 11: 22-36
59. Haynes G, Brahen NH, Hill HF. Plasma sufentanil concentration after intranasal administration in paediatric outpatients [letter]. Can J Anaesth 1993; 40: 286
60. Davis JP, Stiller RL, Cook DR, et al. Effects of cholestatic hepatic disease and chronic renal failure on alfentanil pharmacokinetics in children. Anesth Analg 1989; 68: 579-83
61. Davis PJ, Killian A, Stiller RL, et al. Alfentanil pharmacokinetics in premature infants and older children [abstract]. Anesthesiology 1988; 69: A758
62. Collins C, Koren G, Crean P, et al. Fentanyl pharmacokinetics and hemodynamic effects in preterm infants during ligation of patent ductus arteriosus. Anesth Analg 1985; 64: 1078-80
63. Koehntop DE, Rodman JH, Brundage DM, et al. Pharmacokinetics of fentanyl in neonates. Anesth Analg 1986; 65: 227-32
64. Mannering FJ. Drug metabolism in the newborn. FASEB J 1985; 44: 2302
65. Killian A, Davis PJ, Stiller RL, et al. Influence of gestational age on pharmacokinetics of alfentanil in neonates. Dev Pharmacol Ther 1990; 15: 82-6
66. Roure P, Jean N, Leclerc AC, et al. Pharmacokinetics of alfentanil in children undergoing surgery. Br J Anaesth 1987; 59: 1437-40
67. Singleton MA, Rosen JI, Fisher DM. Pharmacokinetics of fentanyl for infants and adults [abstract]. Anesthesiology 1984; 61: A440
68. Meistelman C, Saint-Maurice C, Lepaul M, et al. A comparison of alfentanil pharmacokinetics in children and adults. Anesthesiology 1987; 66: 13-16
69. Goresky GV, Koren G, Sabourin MA, et al. The pharmacokinetics of alfentanil in children. Anesthesiology 1987; 67: 654-9
70. Koren G, Goresky G, Crean P, et al. Pediatric fentanyl dosing based on pharmacokinetics during cardiac surgery. Anesth Analg 1984; 63: 577-82
71. Greeley WJ, de Bruijn NP. Changes in sufentanil pharmacokinetics within the neonatal period. Anesth Analg 1988; 67: 86-90
72. Scott JC, Stanski DR. Decreased fentanyl and alfentanil dose requirements with age: a simultaneous pharmacokinetic and pharmacodynamic evaluation. J Pharmacol Exp Ther 1987; 240: 159-63
73. Helmers JHJH, van Peer A, Noordiun H, et al. Sufentanil kinetics in the elderly [abstract]. Proceedings of the 7th European Congress of Anaesthesiology: 1986; Vienna, 188
74. Helmers JHJH, van Leeuwen L, Zuurmond WWM. Sufentanil pharmacokinetics in young adult and elderly surgical patients. Eur J Anaesthesiol 1994; 11: 181-5
75. Hudson RJ, Thomson IR, Burgess PM, et al. Alfentanil pharmacokinetics in patients undergoing abdominal aortic surgery. Can J Anaesth 1991; 38: 61-67
76. Helmers JHJH, van Peer A, Woestenborghs R, et al. Alfentanil pharmacokinetics in elderly patients. Clin Pharmacol Ther 1984; 36: 239-43
77. Van Beem H, van Peer A, Gasparini R, et al. Pharmacokinetics of alfentanil during and after a fixed rate infusion. Br J Anaesth 1989; 62: 610-5
78. Bentley JB, Finley JH, Humphrey LR, et al. Obesity and alfentanil pharmacokinetics [abstract]. Anesth Analg 1983; 62: 251
79. Maitre PO, Ausems ME, Vozeh S, et al. Evaluating the accuracy of using population pharmacokinetic data to predict plasma concentrations of alfentanil. Anesthesiology 1987; 67: 59-67
80. Bentley JB, Borel JD, Gillespie TJ, et al. Fentanyl pharmacokinetics in obese and nonobese patients [abstract]. Anesthesiology 1981; 55: A177
81. Schwartz AE, Matteo RS, Ornstein E, et al. Pharmacokinetics of sufentanil in obese patients. Anesth Analg 1991; 73: 790-3
82. Meuldermans WEG, Hurkmans RMA, Heykants JJP. Plasma protein binding and distribution of fentanyl, sufentanil, alfentanil and lofentanil in blood. Arch Int Pharmacodyn Ther 1982; 257: 4-19
83. Meistelman C, Toubas F, Levron JC, et al. Plasma protein binding in mother and newborn infant of fentanyl and alfentanil [abstract]. Anesthesiology 1985; 63: A373
84. Meistelman C, Benhamou D, Barre J, et al. Effects of age on plasma protein binding of sufentanil. Anesthesiology 1990; 72: 470-3
85. 1-acid glycoprotein, albumin and serum. Int J Clin Pharmacol Ther Toxicol 1991; 29: 96-102
86. Meistelman C, Levron JC, Barre J, et al. Effects of increased alpha 1-acid glycoprotein in cancer patients on pharmacokinetics of alfentanil [abstract]. Anesthesiology 1988; 69: A602
87. Bailey PL, Stanley TH. Intravenous opioid anesthetics. In: Miller RD, editor. Anesthesia. 4th ed. New York: Churchill Livingstone, 1994: 291-388
88. Hug Jr CC, Burm AGL, de Lange S, et al. Alfentanil pharmacokinetics and protein binding before and after cardiopulmonary bypass (CPB) [abstract]. Proceedings of the 5th Annual Meeting of the Society of Cardiovascular Anesthesiologists: 1983; San Diego, 76
89. Hug Jr CC, Burm AGL, de Lange S. Alfentanil pharmacokinetics in cardiac surgical patients. Anesth Analg 1994; 78: 231-9
90. Kumar K, Ballantyne J, Bowie D, Laney G. Effect of cardiopulmonary bypass (CPB) on the plasma protein binding of alfentanil (alf) [abstract]. Pharm Res 1994; 11: S439
91. Ferrier C, Marty J, Bouffard MD, et al. Alfentanil pharmacokinetics in patients with cirrhosis. Anesthesiology 1985; 62: 480-4
92. Höllt V, Teschemacher H. Hydrophobic interactions responsible for unspecific binding of morphine-like drugs. Naunyn-Schmiedebergs Arch Pharmacol 1975; 288: 163-77
93. Schwartz AE, Matteo RS, Ornstein E, et al. Pharmacokinetics of sufentanil in neurosurgical patients undergoing hyperventilation. Br J Anaesth 1989; 63: 385-8
94. Lüllmann H, Martins BS, Peters T. pH-dependent accumulation of fentanyl, lofentanil, alfentanil by heating guinea pig atria. Br J Anaesth 1985; 57: 1012-7
95. Williams RL. Drug administration in hepatic disease. New Engl J Med 1984; 309: 1616-22
96. Lemmens HJM. Pharmacokinetic-pharmacodynamic relationships for opioids in balanced anaesthesia. Clin Pharmacokinet 1995; 29: 231-42
97. Marshall JS, Williams S. Serum inhibitors of desialylated glycoprotein binding to hepatocyte membranes. Biochem Biophys Acta 1978; 543: 41-52
98. Williams RL, Benet LZ. Drug pharmacokinetics in cardiac and hepatic disease. Ann Rev Pharmacol Toxicol 1980; 20: 389-413
99. Chauvin M, Bonnet F, Montembault C, et al. The influence of hepatic plasma flow on alfentanil plasma concentration plateaus achieved with an infusion model. Anesth Analg 1986; 65: 999-1003
100. Reitz J, MacKichan JJ, Hoffer L, et al. Reduced plasma clearance of alfentanil associated with prolonged major intra-abdominal surgery. Anesth Analg 1984; 63: 265
101. Haberer JP, Schoeffler P, Coudere E, et al. Fentanyl pharmacokinetics in anaesthetized patients with cirrhosis. Br J Anaesth 1982; 54: 1267-70
102. Hug Jr CC, Murphy MR, Sampson JF, et al. Biotransformation of morphine and fentanyl in anhepatic dogs [abstract]. Anesthesiology 1981; 55: A261
103. Chauvin M, Ferrier C, Haberer JP, et al. Sufentanil pharmacokinetics in patients with cirrhosis. Anesth Analg 1989; 68: 1-4
104. Hudson RJ, Thomson IR, Cannon JF, et al. Pharmacokinetics of fentanyl in patients undergoing abdominal aortic surgery. Anesthesiology 1986; 64: 334-8
105. Sjoholm I, Kober A, Odar-Cederlof I, et al. Protein binding of drugs in uremic and normal serum: the role of endogenous binding inhibitors. Biochem Pharmacol 1976; 25: 1205-13
106. Piafsky KM. Disease-induced changes in the plasma binding of basic drugs. Clin Pharmacokinet 1980; 5: 246-62
107. Van Peer A, Vercauteren M, Noorduin H. Alfentanil kinetics in renal insufficiency. Eur J Clin Pharmacol 1986; 30: 245-9
108. Chauvin M, Lebrault C, Levron JC, et al. Pharmacokinetics of alfentanil in chronic renal failure. Anesth Analg 1987; 66: 53-6
109. Bower S. Plasma protein binding of fentanyl: the effect of hyperlipoproteinaemia and chronic renal failure. J Pharm Pharmacol 1981; 34: 102-6
110. Bovill JG, Sebel PS. Pharmacokinetics of high dose fentanyl: a study in patients undergoing cardiac surgery. Br J Anaesth 1980; 52: 795-801
111. Buylaert WA, Herregods LL, Mortier EP, et al. Cardiopulmonary bypass and the pharmacokinetics of drugs: an update. Clin Pharmacokinet 1989; 17: 10-22
112. Hall R. The pharmacokinetic behaviour of opioids administered during cardiac surgery. Can J Anaesth 1991; 38: 747-56
113. Rosen D, Rosen K, Davidson B, et al. Fentanyl uptake by the Scimed membrane oxygenator. J Cardiothorac Vasc Anesth 1988; 2: 619-22
114. Durkan W, Lonergan M, Schwartz S, et al. Effect of membrane oxygenators on sufentanil blood levels during cardiopulmonary bypass [abstract]. Anesth Analg 1988; 67: S54
115. Skacel M, Knott C, Reynolds F, et al. Extracorporeal circuit sequestration of fentanyl and alfentanil. Br J Anaesth 1986; 58: 947-9
116. Den Hollander J, Hennis PJ, Burm AGL, et al. Pharmacokinetics of alfentanil before and after cardiopulmonary bypass in pediatric patients undergoing cardiac surgery: Part I. J Cardiothorac Vasc Anesth 1992; 6: 308-12
117. Okutani R, Koski G, Gelb C, et al. High dose sufentanil does not prevent catecholamine responses to hypothermic cardiopulmonary bypass [abstract]. Anesth Analg 1988; 67: S160
118. Kosku III AJ, Romagnoli A, Kramer WG. Effect of cardiopulmonary bypass on fentanyl distribution and elimination. Clin Pharmacol Ther 1981; 29: 100-6
119. Hug Jr CC, Moldenhauer CC. Pharmacokinetics and dynamics of fentanyl infusions in cardiac surgical patients [abstract]. Anesthesiology 1982; 57: A45
120. Holley FO, Ponganis KV, Stanski R. Effect of cardiopulmonary bypass on the pharmacokinetics of drugs. Clin Pharmacokinet 1982; 7: 234-51
121. Bentley JB, Cohanan III TJ, Cork RC. Fentanyl sequestration in kings during cardiopulmonary bypass. Clin Pharmacol Ther 1983; 34: 703-6
122. Roerig DL, Kotrly KJ, Ahlf SB, et al. Effect of propranolol on the first pass uptake of fentanyl in the human and rat lung. Anesthesiology 1989; 71: 62-8
123. Boer F, Bovill JG, Burm AGL, et al. Uptake of sufentanil, alfentanil and morphine in the lungs of patients about to undergo coronary artery surgery. Br J Anaesth 1992; 68: 370-5
124. Janicki PK, James MF, Erskine WA. Propofol inhibits enzymatic degradation of alfentanil and sufentanil by isolated liver microsomes in vitro. Br J Anaesth 1992; 68: 311-2
125. Kharasch ED, Hill HF, Eddy AC. Influence of dexmedetomidine and clonidine on human liver microsomal alfentanil metabolism. Anesthesiology 1991; 75: 520-4
126. Nimmo WS, Thompson PG, Prescott LF. Microsomal enzyme induction after halothane anesthesia. Br J Clin Pharmacol 1981; 12: 433-4
127. Bartkowski RR, Goldberg ME, Huffnagle S, et al. Sufentanil disposition: is it affected by erythromycin administration? Anesthesiology 1993; 78: 260-5
128. Sedman AJ. Cimetidine: drug interactions. Am J Med 1984; 76: 109-12
129. 2-receptors on fentanyl metabolism [abstract]. Pharmacologist 1982; 24: 145
130. Klotz U, Kroemer HK. The drug interaction potential of ranitidine: an update. Pharmacol Ther 1991; 50: 233-44
131. Shafer SL, Varvel JR. Pharmacokinetics, pharmacodynamics, and rational opioid selection. Anesthesiology 1991; 74: 53-63
132. Shaler SL, Stanski DR. Improving the clinical utility of anesthetic drug pharmacokinetics [editorial]. Anesthesiology 1992; 76: 327-30
133. Youngs EJ, Shafer SL. Pharmacokinetic parameters relevant to recovery from opioids. Anesthesiology 1994; 81: 833-42
134. Hughes MA, Glass PSA, Jacobs JR. Context-sensitive half-time in multicompartment pharmacokinetic models for intravenous anesthetic drugs. Anesthesiology 1992; 76: 334-41
135. Bailey JM. Technique for quantifying the duration of intravenous anesthetic effect. Anesthesiology 1995; 83: 1095-103
136. Schnider TW, Shafer SL. Evolving clinically useful predictors of recovery from intravenous anesthetics [editorial]. Anesthesiology 1995; 83: 902-5